Search results
Results from the WOW.Com Content Network
Antivirulence is the concept of blocking virulence factors. [1] In regards to bacteria, the idea is to design agents that block virulence rather than kill bacteria en masse, as the current regime results in much more selective pressure (on antibiotic resistance).
Virulence is a pathogen's or microorganism's ability to cause ... Immune response inhibitors Many bacteria produce virulence factors that inhibit the host's immune ...
Examples of virulence factors for Staphylococcus aureus are hyaluronidase, protease, coagulase, lipases, deoxyribonucleases and enterotoxins. Examples for Streptococcus pyogenes are M protein , lipoteichoic acid , hyaluronic acid capsule, destructive enzymes (including streptokinase , streptodornase , and hyaluronidase ), and exotoxins ...
Nelfinavir is a competitive inhibitor [4] (2 nM) which is designed to bind tightly and is not cleaved due to the presence of a hydroxyl group as opposed to a keto group in the middle amino acid residue mimic, which would be otherwise S-phenylcysteine. All protease inhibitors bind to the protease, the precise mode of binding determines how the ...
Ribbon diagram of the Cif dimer from P. aeruginosa PA14. From . The CFTR inhibitory factor (Cif) is a protein virulence factor secreted by the Gram-negative bacteria Pseudomonas aeruginosa [1] and Acinetobacter nosocomialis. [2]
In pathogenic bacteria, curlis can contribute to virulence by helping in cell invasion and activating the innate immune response. Knowing how curli fibers are made, and how the type VIII secretion system works, can help develop an inhibitor to stop or reduce the production of these curli fibers and overall reduce the virulence of the bacteria ...
Viral infectivity factor, or Vif, is an accessory protein found in HIV and other lentiviruses.Its role is to disrupt the antiviral activity of the human enzyme APOBEC (specifically APOBEC3G, "A3G" in short, and other A3 enzymes) by targeting it for ubiquitination and cellular degradation.
The first protease inhibitor approved by the U.S. Food and Drug Administration (FDA). Ritonavir: Norvir: AbbVie: U.S. patent 5,541,206: March 1, 1996: AbbVie was part of Abbott Laboratories when patent was granted. As well as being a protease inhibitor in its own right, ritonavir inhibits the breakdown of other protease inhibitors.